查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1517571

真菌性角膜炎治療市場 - 按治療類型{醫療[藥物類別、給藥途徑]、手術}、適應症、真菌種類、年齡層、最終用戶、全球預測

Fungal Keratitis Treatment Market - By Treatment Type {Medical [Drug Class, Route of Administration], Surgical}, Indication, Fungal Species, Age Group, End-user, Global Forecast
出版日期: | 出版商: Global Market Insights Inc. | 英文 362 Pages | 商品交期: 2-3個工作天內

價格
簡介目錄

由於真菌性角膜炎在全球的盛行率不斷增加，2024-2032年全球真菌性角膜炎治療市場將以6.1%的複合年成長率成長。根據 EyeWiki，真菌性角膜炎是一種日益嚴重的全球現象，其盛行率在全球範圍內不斷增加。病例增加是由多種因素造成的，包括隱形眼鏡衛生不當、眼睛受傷和農業實踐。隨著角膜真菌感染的盛行率持續上升，對快速診斷和有效治療措施的需求也隨之增加。病例數量的不斷增加增加了對創新治療解決方案的需求，並促進了應對此臨床挑戰所需的研究和開發。

一個明顯的趨勢是越來越關注聯合治療。有鑑於真菌對傳統抗真菌藥物抗藥性的挑戰，研究人員和臨床醫生正在探索抗真菌藥物的協同組合，以提高療效並最大限度地降低產生抗藥性的風險。透過結合多種治療方法，如抗真菌眼藥水、全身性藥物治療以及角膜膠原交聯等輔助治療，醫師試圖改善治療效果並加速真菌性角膜炎的癒合。

整個真菌性角膜炎治療產業根據治療類型、適應症、真菌種類、年齡層、最終用戶和地區進行分類。

到 2032 年，深層角膜炎部分將迅速成長，因為深層角膜炎的特徵是真菌滲透到角膜更深層，如果不及時治療，會增加視力喪失和角膜穿孔的風險。因此，有效治療深層角膜炎需要積極的抗真菌治療，通常與角膜移植或治療性角膜移植等外科手術相結合。隨著手術技術的進步和標靶抗真菌藥物的開發，深層角膜炎患者的預後顯著改善，增加了根據角膜受累的嚴重程度和深度量身定做的綜合治療方案的需求。

到 2032 年，由於職業暴露、隱形眼鏡的使用和免疫系統減弱會增加成年人對真菌性角膜炎的易感性，成人市場將出現良好成長。此外，戶外活動和農業工作等生活方式因素會增加眼睛受傷和接觸真菌疾病的風險。因此，成人在尋求真菌性角膜炎治療的患者中佔很大比例，這增加了針對其獨特的臨床需求和風險狀況而量身定做的有效治療干預措施的需求。

到 2032 年，歐洲真菌性角膜炎治療產業將顯著成長，其特點是臨床知識、研究創新和監管監督的融合。歐洲擁有強大的醫療保健基礎設施和眼科研究生態系統，促進學術機構、醫療保健提供者和製藥公司之間的合作，開發真菌性角膜炎的療法。英國、德國和法國等國家處於眼科領域臨床研究和治療創新的前沿，這正在推動市場成長和新療法的採用。此外，嚴格的監管標準和報銷實踐確保患者能夠獲得優質護理和創新治療。

目錄

第 1 章：方法與範圍

第 2 章：執行摘要

第 3 章：產業洞察

  • 產業生態系統分析
  • 產業影響力
    • 成長動力
      • 眼部感染的發生率增加
      • 老年人口不斷增加
      • 配戴隱形眼鏡的比例不斷增加
      • 增加研發活動
    • 產業陷阱與挑戰
      • 與抗真菌藥物相關的副作用
  • 成長潛力分析
  • 監管環境
  • 波特的分析
  • PESTEL分析

第 4 章：競爭格局

  • 介紹
  • 公司矩陣分析
  • 主要市場參與者的競爭分析
  • 競爭定位矩陣
  • 戰略儀表板

第 5 章：市場估計與預測：按治療類型，2021 - 2032 年

  • 主要趨勢
  • 藥物治療
    • 藥品類
      • 多烯
        • 納他黴素
        • 兩性黴素B
      • 唑類
        • 三唑
        • 伏立康唑
        • 氟康唑
        • 伊曲康唑
        • 泊沙康唑
        • 咪唑類
        • 益康唑
        • 咪康唑
        • 酮康唑
      • 其他藥物類別
    • 給藥途徑
      • 專題
      • 口服
      • 可注射
  • 手術治療

第 6 章：市場估計與預測：按指標分類，2021 - 2032 年

  • 主要趨勢
  • 表淺角膜炎
  • 深層角膜炎

第 7 章：市場估計與預測：按真菌種類，2021 - 2032

  • 主要趨勢
  • 鐮刀菌屬
  • 麴菌屬
  • 念珠菌屬
  • 頭孢菌屬
  • 其他物種

第 8 章：市場估計與預測：按年齡分類，2021 - 2032

  • 主要趨勢
  • 孩子們
  • 成年人
  • 老年科

第 9 章：市場估計與預測：按最終用戶分類，2021 - 2032 年

  • 主要趨勢
  • 醫院
  • 診所
  • ASC
  • 其他最終用戶

第 10 章：市場估計與預測：按地區，2021 - 2032

  • 主要趨勢
  • 北美洲
    • 美國
    • 加拿大
  • 歐洲
    • 德國
    • 英國
    • 法國
    • 西班牙
    • 義大利
    • 荷蘭
    • 歐洲其他地區
  • 亞太地區
    • 中國
    • 日本
    • 印度
    • 澳洲
    • 韓國
    • 亞太地區其他地區
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 拉丁美洲其他地區
  • 中東和非洲
    • 南非
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 中東和非洲其他地區

第 11 章：公司簡介

  • Alvogen
  • Aurolab
  • Bausch Health Companies Inc.
  • Eyevance Pharmaceuticals LLC
  • Gilead Biosciences, Inc.
  • Glenmark Pharmaceuticals Ltd.
  • Leadiant Biosciences, Inc.
  • Merck & Co. Inc.
  • Novo Holdings A/S (Xellia Pharmaceuticals)
  • Pfizer Inc.
簡介目錄
Product Code: 9024

Global Fungal Keratitis Treatment Market will grow at 6.1% CAGR during 2024-2032 due to the increasing prevalence of Keratitis Fungal globally. According to EyeWiki, fungal keratitis is a growing global phenomenon with increasing prevalence worldwide. The increase in cases is due to several factors, including improper contact lens hygiene, eye injuries, and agricultural practices. As the prevalence of corneal fungal infections continues to rise, the need for rapid diagnosis and effective treatment measures increases. The growing number of cases increases the demand for innovative treatment solutions and promotes the research and development needed to address this clinical challenge.

A visible trend is an increasing focus on combination therapy. Recognizing the challenges presented by fungal resistance to conventional antifungal drugs, researchers and clinicians are exploring synergistic combinations of antifungal agents to improve efficacy and minimize the risk of developing resistance. By combining several treatments, such as antifungal eye drops, systemic medications, and adjuvant therapy, such as corneal collagen cross-linking, doctors try to improve treatment results and speed up the healing of fungal keratitis.

The overall Fungal Keratitis Treatment industry is classified based on treatment type, indication, fungal species, age group, end user, and region.

The deep keratitis segment will grow rapidly through 2032, as deep keratitis, characterized by fungal penetration into the deeper layers of the cornea, carries an increased risk of vision loss and corneal perforation if left untreated. As such, effective treatment of deep keratitis requires aggressive antifungal therapy, often combined with surgical procedures such as corneal transplantation or therapeutic keratoplasty. With advances in surgical techniques and the development of targeted antifungal agents, the prognosis of patients with deep keratitis has improved significantly, increasing the demand for comprehensive treatment regimens tailored to the severity and depth of corneal involvement.

The adult segment will grow decently through 2032 as occupational exposure, use of contact lenses, and weakened immune systems increase the susceptibility of adults to fungal keratitis. In addition, lifestyle factors such as outdoor activities and agricultural work increase the risk of eye injuries and exposure to fungal diseases. As such, adults represent a significant proportion of patients seeking treatment for fungal keratitis, increasing the demand for effective therapeutic interventions tailored to their unique clinical needs and risk profiles.

Europe Fungal Keratitis Treatment industry will grow significantly through 2032, characterized by the convergence of clinical knowledge, research innovation, and regulatory oversight. Europe has a strong healthcare infrastructure and ophthalmic research ecosystem that fosters collaboration between academic institutions, healthcare providers, and pharmaceutical companies to develop therapies for fungal keratitis. Countries such as the United Kingdom, Germany, and France are at the forefront of clinical research and therapeutic innovation in the field of ophthalmology, which is driving market growth and the adoption of new treatments. In addition, strict regulatory standards and reimbursement practices ensure that patients have access to quality care and innovative treatments.

Table of Contents

Chapter 1 Methodology & Scope

  • 1.1 Market scope & definitions
  • 1.2 Research design
    • 1.2.1 Research approach
    • 1.2.2 Data collection methods
  • 1.3 Base estimates & calculations
    • 1.3.1 Base year calculation
    • 1.3.2 Key trends for market estimation
  • 1.4 Forecast model
  • 1.5 Primary research and validation
    • 1.5.1 Primary sources
    • 1.5.2 Data mining sources

Chapter 2 Executive Summary

  • 2.1 Industry 360 degree synopsis

Chapter 3 Industry Insights

  • 3.1 Industry ecosystem analysis
  • 3.2 Industry impact forces
    • 3.2.1 Growth drivers
      • 3.2.1.1 Increasing incidence of eye infections
      • 3.2.1.2 Growing geriatric population
      • 3.2.1.3 Increasing prevalence of contact lens wear
      • 3.2.1.4 Increasing research and development activities
    • 3.2.2 Industry pitfalls & challenges
      • 3.2.2.1 Side effects associated with the antifungal medications
  • 3.3 Growth potential analysis
  • 3.4 Regulatory landscape
  • 3.5 Porter's analysis
  • 3.6 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

  • 4.1 Introduction
  • 4.2 Company matrix analysis
  • 4.3 Competitive analysis of major market players
  • 4.4 Competitive positioning matrix
  • 4.5 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Treatment Type, 2021 - 2032 ($ Million)

  • 5.1 Key trends
  • 5.2 Medical treatment
    • 5.2.1 Drug class
      • 5.2.1.1 Polyenes
        • 5.2.1.1.1 Natamycin
        • 5.2.1.1.2 Amphotericin B
      • 5.2.1.2 Azoles
        • 5.2.1.2.1 Triazole
        • 5.2.1.2.1.1 Voriconazole
        • 5.2.1.2.1.2 Fluconazole
        • 5.2.1.2.1.3 Itraconazole
        • 5.2.1.2.1.4 Posaconazole
        • 5.2.1.2.2 Imidazoles
        • 5.2.1.2.2.1 Econazole
        • 5.2.1.2.2.2 Miconazole
        • 5.2.1.2.2.3 Ketoconazole
      • 5.2.1.3 Other drug classes
    • 5.2.2 Route of administration
      • 5.2.2.1 Topical
      • 5.2.2.2 Oral
      • 5.2.2.3 Injectable
  • 5.3 Surgical treatment

Chapter 6 Market Estimates and Forecast, By Indication, 2021 - 2032 ($ Million)

  • 6.1 Key trends
  • 6.2 Superficial keratitis
  • 6.3 Deep keratitis

Chapter 7 Market Estimates and Forecast, By Fungal Species, 2021 - 2032 ($ Million)

  • 7.1 Key trends
  • 7.2 Fusarium
  • 7.3 Aspergillus
  • 7.4 Candida
  • 7.5 Cephalosporium
  • 7.6 Other species

Chapter 8 Market Estimates and Forecast, By Age Group, 2021 - 2032 ($ Million)

  • 8.1 Key trends
  • 8.2 Children
  • 8.3 Adults
  • 8.4 Geriatric

Chapter 9 Market Estimates and Forecast, By End-User, 2021 - 2032 ($ Million)

  • 9.1 Key trends
  • 9.2 Hospitals
  • 9.3 Clinics
  • 9.4 ASCs
  • 9.5 Other end-users

Chapter 10 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Mn)

  • 10.1 Key trends
  • 10.2 North America
    • 10.2.1 U.S.
    • 10.2.2 Canada
  • 10.3 Europe
    • 10.3.1 Germany
    • 10.3.2 UK
    • 10.3.3 France
    • 10.3.4 Spain
    • 10.3.5 Italy
    • 10.3.6 Netherlands
    • 10.3.7 Rest of Europe
  • 10.4 Asia Pacific
    • 10.4.1 China
    • 10.4.2 Japan
    • 10.4.3 India
    • 10.4.4 Australia
    • 10.4.5 South Korea
    • 10.4.6 Rest of Asia Pacific
  • 10.5 Latin America
    • 10.5.1 Brazil
    • 10.5.2 Mexico
    • 10.5.3 Rest of Latin America
  • 10.6 Middle East and Africa
    • 10.6.1 South Africa
    • 10.6.2 Saudi Arabia
    • 10.6.3 UAE
    • 10.6.4 Rest of Middle East and Africa

Chapter 11 Company Profiles

  • 11.1 Alvogen
  • 11.2 Aurolab
  • 11.3 Bausch Health Companies Inc.
  • 11.4 Eyevance Pharmaceuticals LLC
  • 11.5 Gilead Biosciences, Inc.
  • 11.6 Glenmark Pharmaceuticals Ltd.
  • 11.7 Leadiant Biosciences, Inc.
  • 11.8 Merck & Co. Inc.
  • 11.9 Novo Holdings A/S (Xellia Pharmaceuticals)
  • 11.10 Pfizer Inc.